Structures by: Neves P. P.
Total: 15
Ticlopidine hydrochloride form II
C14H15Cl2NS
CrystEngComm (2011) 13, 19 5737
a=5.4410(2)Å b=12.2260(4)Å c=21.7050(7)Å
α=90° β=101.040(2)° γ=90°
Doxycycline monohydrate
C22H24N2O8,H2O
CrystEngComm (2012) 14, 7 2532
a=5.9241(1)Å b=9.4808(2)Å c=18.5568(4)Å
α=90.00° β=91.192(2)° γ=90.00°
Lead Barium Zirconium Titanium Oxide
Pb0.9Ba0.1Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=5.78826(5)Å b=5.78826(7)Å c=14.27227(16)Å
α=90.00000° β=90.00000° γ=120.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.9Ba0.1Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.10755(3)Å b=4.10755(3)Å c=4.10755(3)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.8Ba0.2Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=5.79776(5)Å b=5.79776(5)Å c=14.26758(15)Å
α=90.00000° β=90.00000° γ=120.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.8Ba0.2Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.111610(17)Å b=4.111610(17)Å c=4.111610(17)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.7Ba0.3Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.11241(6)Å b=4.11241(6)Å c=4.11241(6)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Barium Zirconium Titanium Oxide
Pb0.6Ba0.4Zi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.11604(2)Å b=4.11604(2)Å c=4.11604(2)Å
α=90.00000° β=90.00000° γ=90.00000°
Lead Zirconium Titanium Oxide
PbZi0.65Ti0.35O3
Acta Crystallographica, Section B (2007) 63, 5 713-718
a=5.7779174(9)Å b=5.7779174(9)Å c=14.26920510(15)Å
α=90.00000° β=90.00000° γ=120.00000°
Lead Zirconium Titanium Oxide
PbZi0.65Ti0.35O3
Acta Crystallographica Section B (2007) 63, 5 713-718
a=4.09836(3)Å b=4.09836(3)Å c=4.09836(3)Å
α=90.00000° β=90.00000° γ=90.00000°
Doxycycline chloride salt dihydrate
C22H25N2O81,2(H2O1),Cl11)
Crystal Growth & Design (2014) 14, 8 3711
a=11.0979(1)Å b=12.7557(1)Å c=16.8829(2)Å
α=90° β=90° γ=90°
Doxycycline acetic acid dihydrate
C22H24N2O8,2(O1H2),1(C2O2H4)
Crystal Growth & Design (2014) 14, 8 3711
a=6.4753(2)Å b=9.0970(4)Å c=42.8077(16)Å
α=90° β=90° γ=90°
Chlortalidone Form I
C14H11ClN2O4S
Crystal Growth & Design (2009) 9, 7 3235
a=6.2270(2)Å b=8.3870(3)Å c=14.3640(4)Å
α=92.141(2)° β=101.050(2)° γ=107.024(2)°
Chlortalidone Form III
C14H11ClN2O4S
Crystal Growth & Design (2009) 9, 7 3235
a=7.9957(2)Å b=8.1467(2)Å c=11.4761(3)Å
α=80.448(2)° β=79.277(2)° γ=86.106(2)°
Doxycycline nitrate salt hemihydrate
2(C22H25N2O8)1,2(N1O3)1,1(O1H2)
Crystal Growth & Design (2014) 14, 8 3711
a=8.0679(2)Å b=8.9156(3)Å c=16.6791(5)Å
α=77.872(2)° β=87.581(2)° γ=74.133(3)°